In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Participants will receive treatment until eventually disease progression or maybe the contributors are unable to tolerate the study drugs. - "Our study discovered the essential job on the KLF16/MYC regulatory axis https://stepheny211kvf3.wikirecognition.com/user